肺癌筛查项目质量指标——综述与建议:国际肺癌研究协会德尔菲流程研究
国际肺癌研究协会(IASLC)的20名多学科成员通过德尔菲流程,经过信息/讨论环节和两轮匿名投票,在11个肺癌筛查路径域类别中的10个里确定了20项基本质量指标和6项理想质量指标。共识定义为在五点李克特量表上80%或以上投票同意或强烈同意。这些推荐的质量指标应在肺癌筛查项目开发中予以考虑。
要点
- 20名多学科成员通过德尔菲流程确定20项基本和6项理想肺癌筛查质量指标。
- 共识标准为五点李克特量表上80%或以上投票同意或强烈同意。
- 质量指标覆盖11个路径域类别中的10个,包括准入、戒烟、影像、依从性、诊断、结局、危害、治疗、等待时间和公平性。
核心结论
- 专家组成员综述后提供了推荐的肺癌筛查质量指标,这些指标应在肺癌筛查项目开发中予以考虑。
研究设计与样本
- 国际肺癌研究协会(IASLC)的20名多学科成员采用德尔菲流程开发共识质量指标。
- 成员在信息/讨论环节和两轮匿名投票中考虑了50项质量指标。
- 在五点李克特量表上80%或以上投票同意或强烈同意确定为共识。
主要发现
- 在11个肺癌筛查路径域类别中的10个里确定了20项基本质量指标和6项理想质量指标。
- 确定的领域包括:准入(符合条件者接受筛查的比例)、戒烟(当前吸烟者获得戒烟干预的比例)、影像(需要临床诊断评估的筛查比例、扫描结果分发、需要早期随访的扫描比例、基线或常规扫描具有可操作额外发现的比例)、依从性(年度或定期扫描、早期临时扫描、临床诊断评估)、诊断(疑似肺癌扫描接受临床检查的比例、接受侵入性诊断程序的比例)、结局(癌症检出率、分期分布、间期癌症率)、危害(侵入性程序后严重并发症的数量和比例、侵入性程序或手术后非肺癌诊断、侵入性程序后30天死亡率)、治疗(早期癌症接受治愈性意图治疗的比例)、等待时间(疑似肺癌扫描到明确诊断、早期疾病个体到治愈性意图治疗、扫描完成到向初级保健提供者和参与者报告结果)、公平性(定期筛查依从性、早期癌症治疗、戒烟干预提供、疑似肺癌筛查临床检查中的种族、性别和社会经济差异)。
关键数值与推荐
- 共识定义为在五点李克特量表上80%或以上投票同意或强烈同意。
- 确定了20项基本质量指标和6项理想质量指标,覆盖11个肺癌筛查路径域类别中的10个。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Lung cancer screening (LCS) using low-dose-computed tomography reduces lung cancer mortality in high-risk individuals. Evaluating and monitoring LCS programs are important to ensure and improve quality, efficiency, and participant outcomes. There is no agreement on LCS quality indicators (QIs). METHODS: Twenty multidisciplinary members of the International Association for the Study of Lung Cancer used a Delphi process to develop consensus QIs. They considered 50 QIs during information/discussion sessions and two anonymous voting rounds. In total, 80% or more voting agree or strongly agree on a five-point Likert scale determined consensus. RESULTS: Twenty essential and six desirable QIs were identified in 10 of 11 LCS pathway domain categories (ENTRY: Proportion eligible who got screened; SMOKING_CESSATION: Proportion of current-smoking individuals offered cessation interventions; IMAGING: Proportion screened requiring clinical diagnostic assessment, scan results distribution, proportion scans requiring early follow-up, proportion baseline or regular scans with actionable additional findings; ADHERENCE to: Annual or regular scans, early interim scans, clinical diagnostic assessment; DIAGNOSTIC: Proportion suspicious-for-lung-cancer scans receiving clinical investigation, undergoing invasive diagnostic procedures; OUTCOMES: Cancer detection rate, stage distribution, interval cancer rate; HARMS: Number and proportion of serious complications after invasive procedures, non-lung cancer diagnoses after invasive procedures or surgery, 30-day mortality after invasive procedure; TREATMENT: Proportion early-stage cancers receiving treatment with curative intent; WAIT_TIMES: Suspicious-for-lung-cancer scan to definitive diagnosis, to curative-intent treatment for individuals with early-stage disease, scan completion to reporting results to primary care provider and participant; EQUITY: Race, sex, and socioeconomic differences in adherence to regular screens, early-stage cancer treatment, offer of smoking cessation interventions, clinical investigation of suspicious-for-lung-cancer screens). CONCLUSIONS: A review among panel members provided recommended LCS QIs that should be considered in the development of LCS initiatives.
引用
- Tammemägi MC, Borondy-Kitts A, Field JK, et al. Lung Cancer Screening Program Quality Indicators-Review and Recommendations: An International Association for the Study of Lung Cancer Delphi Process Study. J Thorac Oncol. 2025. PMID: 39864549. doi:10.1016/j.jtho.2025.01.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。